LeMaitre Vascular stock faces a 0.74 EPS miss in Q2

Published on 09/29/2026 at 22:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LeMaitre Vascular stock reported Q2 revenue of USD 70.38 million on August 4, 2026, up 9.6 percent year over year. EPS was USD 0.74 versus USD 0.81 consensus.

LMAT, US52567J1079, Illustration mit AI erstellt.

LeMaitre Vascular (ISIN US52567J1079) reported Q2 2026 revenue of USD 70.38 million, up 9.6 percent year over year, while diluted EPS reached USD 0.74. The results published on August 4, 2026, put growth and earnings quality on different tracks.

Revenue grows while EPS misses

According to MarketBeat on September 26, 2026, quarterly EPS came in at USD 0.74 versus the USD 0.81 consensus estimate. Revenue also fell short of the USD 71.47 million estimate, creating a quantified earnings and sales comparison despite the 9.6 percent annual revenue increase.

The company operates in specialized medical devices for peripheral vascular disease, including vascular grafts, catheters, patches and surgical instruments, according to MarketBeat.

Analyst targets send mixed signals

Argus raised its LMAT price target to USD 89.00 in a report dated September 2, 2026, as shown by Yahoo Finance. The target stands USD 6.11 above the Nasdaq quote of USD 82.89, a 7.37 percent difference.

MarketBeat reported a consensus Hold rating from nine research firms and an average target of USD 110.60 on September 26, 2026. The gap between the average target and the Argus target highlights a wide range of analyst assumptions around growth and valuation.

Stock stays near yearly low

LMAT was last at USD 82.89 on Nasdaq on September 29, 2026, at 4:00 p.m. ET. The quote stood 5.97 percent above the 52-week low of USD 78.22 and below the 52-week high of USD 118.01, while market capitalization was USD 1.9 billion on the same date.

The market response is therefore centered on execution. Revenue expansion remains measurable, but the Q2 EPS miss and the distance between the USD 89.00 Argus target and the USD 110.60 consensus target leave valuation sensitive to future margin delivery.